| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PSMD6-AS2 | Middle East Respiratory Syndrome Coronavirus (EMC_2012 strain of (MERS-CoV)) | MOI = 3 ;
24 hr |
MRC-5 Human fetal lung fibroblast cells | RNA-Seq | 2.180622442 | Upregulation | 4.90E-05 | student's t test | 2020 | 32416070 | |
| PSMD6-AS2 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 5.420991185 | Upregulation | 0.035707764 | student's t test | 2020 | 32416070 | |
| PSMD6-AS2 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 1.795094756 | Upregulation | 1.57E-12 | student's t test | 2020 | 32416070 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose